Extrusion bioprinting forces kill 10-45% of cells before the construct is even finished

Lab teams using extrusion-based bioprinting -- the most common modality for organ-scale constructs -- routinely lose 10-45% of their cells during the print itself due to shear and extensional stress as bioink is forced through the nozzle. So what? Dead cells release damage-associated molecular patterns (DAMPs) that trigger inflammatory cascades in the surviving cells, compromising the construct before it even enters a bioreactor. So what? Researchers must overload their bioinks with 2-5x more cells than needed, which is enormously expensive when using patient-derived iPSCs that cost thousands of dollars per billion cells. So what? The economics of patient-specific bioprinted tissues become prohibitive -- you're paying to grow cells you know will die during printing. Why does this persist? There is a fundamental tradeoff: higher bioink viscosity improves shape fidelity (the print holds its shape) but increases shear stress on cells. Lower viscosity protects cells but produces constructs that slump and lose architecture. No bioink formulation has resolved this tradeoff. Shear-thinning hydrogels help but do not eliminate the problem, and the exponential relationship between shear stress and cell death means small parameter errors cause large viability drops.